Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours Β· Estimated delivery Sep 1 - Sep 6
Ponatinib, a third-generation BCR-ABL inhibitor with potent activity against T315I-mutant leukemia, is under investigation in pediatric relapsed or refractory hematologic malignancies (NCT03934372)
Our team of experts is dedicated to delivering safe, effective, and innovative therapies tailored to your unique needs
Without a delivery system like liposomal technology, these powerful nutrients may never reach their destination
Despite the use of rodents and small mammals being commonplace in research, in particular for the development of novel therapeutic agents, caution still needs to be practiced when extrapolating research data to clinical applications
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
.jpg)